Between 2017 - 2020, 179
patients with 276 oligomets (167 brain lesion, 109 extra-cranial site)
were treated with CK. In extra-cranial mets, 15 were bone mets, 13
lymphnode mets, 11 liver mets, 3 choroidal mets and 1 each adrenal
and pancreas. In 100 accrued brain mets patients with 167 brain lesions, 42 % had lung primary, 32% breast and 9% RCC. One, 3
& 5 fraction SRS was done in 61%, 15% and 24%.SRS dose was 12 Gy in
4%,13-18Gy in 19%, 20-24Gy in 42% and 25-30Gy in 35%. Solitary mets was
in 59%, up to 3 in 32% and >3 in only 9% patients. At
mean follow up 58.8 wks (4-164 wk), 86 had follow up evaluation (39 patients
were alive, 47 expired). Among 32 patients had recurrent brain mets, 20
underwent treatment (12 received re-SRS, 5 WBRT, 3 had surgery). In 22 patients with lung oligomets,
3 had synchronous and 19 had metachronous lung mets. Primary site was colorectal
in 9, thyroid in 3, kidney 4, head neck in 2, liver in 1, endometrium in 1,
pancreas in 1, sarcoma 1. Mean PTV was 21cc (range: 2.8 – 78 cc). 18–24 Gy/1fr,
45-54Gy/3fr, 35-50Gy/1fr & 48Gy/8fr in 6, 8, 5 and 1 patient respectively. Among
17 evaluable patients CR was in 76% (13/17) and PR 12% (2/17). 2 (12%)
papillary carcinoma thyroid patients had progressive disease. At mean Follow up of 11
months, 7 (32%) were alive with controlled disease, 8 (36%) were alive with disease
progression. 2 (9%) had local and distant failure and 10 (45%) had systemic
progression. 2/3 (66%) of choroidal metastasis had CR. In liver metastasis,
8/11 (72%) had CR. In bone metastasis 10/15 (66%) had excellent symptomatic
relief with radiological response.